Thioridazine

硫利达嗪

Report date: 2025/10/09 09:53:02
NME

Base Information

Drug NameThioridazine
Drug Alias Nametioridazina硫醚嗪甲硫哌啶thioridazinethioridazinum +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 2a (5-HT2a) receptor antagonistsDopamine D1 receptor antagonistsDopamine D2 receptor antagonists +[5] 
TargetsSerotonin 2a (5-HT2a) receptorAlpha-1a adrenergic receptorAlpha-1b adrenergic receptor +[5] 
Therapy Area/IndicationsSchizophreniaAnxiety Disorders
Global Approved IndicationsSchizophreniaAnxiety Disorders
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1978/10/18
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusWithdrawn
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovartis Pharma Ag
Active IndicationsN/A
Inactive IndicationsSchizophreniaAnxiety Disorders

Other Information

ATC CodeN05AC02
Related LinksWikipediaDrugBankKEGG